Low expression of PCK2 in breast tumors contributes to better prognosis by inducing senescence of cancer cells
Authors:
- 27 May 2022
- journal article
- research article
- Published by Wiley in IUBMB Life
- Vol. 74 (9) , 896-907
Abstract
Cell cycle arrest, one of the main characteristics of cellular senescence, has been described as a crucial barrier that needs to be bypassed for cancer progression. Typically, cellular senescence can be induced by multiple stresses including telomere shortening, oncogenic activation as well as therapy treatment, and contributes to the inhibition of epithelial–mesenchymal transition (EMT), tumor suppression or progression depending on the senescence‐associated secretory phenotype (SASP) components. However, the mechanisms underlying cancer cell senescence remain partially understood. Here, according to METABRIC database, we identified that patients with senescent‐like breast tumors show better short‐term survival, lower tendency of neoplasm histological grades, lower tumor stages, and negative status of estrogen receptor (ER) and progesterone receptor (PR) compared with non‐senescent ones. Interestingly, Kyoto encyclopedia of genes and genomes (KEGG) analysis identified insulin signaling was significantly repressed in senescent breast tumors. Further verification in cultured breast cancer cells indicated that phosphoenolpyruvate carboxykinase 2 (PCK2) was significantly inhibited after therapy treatment. In addition, knockdown of PCK2 induced a senescent phenotype of breast cancer cells. Moreover, comparing with the non‐senescent group, the senescent breast cancers displayed lower EMT capacity both in patients and breast cancer cell lines after knocking down PCK2. In conclusion, we described for the first time that low expression level of PCK2 may contribute to better prognosis via triggering senescent phenotype and thereby inhibiting EMT capacity in breast cancers.Keywords
This publication has 29 references indexed in Scilit:
- Cellular senescence and its effector programsGenes & Development, 2014
- A complex secretory program orchestrated by the inflammasome controls paracrine senescenceNature Cell Biology, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Senescence: a new weapon for cancer therapyTrends in Cell Biology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor SuppressorPLOS Biology, 2008
- Chemokine Signaling via the CXCR2 Receptor Reinforces SenescenceCell, 2008
- Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular SenescenceCell, 2003
- A biomarker that identifies senescent human cells in culture and in aging skin in vivo.Proceedings of the National Academy of Sciences, 1995